

SUPPLEMENT ARTICLE

Diagnosis and Management of Waldenstrom's Macroglobulinemia

Steven P. Treon^{1,2}  | Shayna Sarosiek^{1,2}  | Jorge J. Castillo^{1,2} 

¹Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, Massachusetts, USA | ²Harvard Medical School, Boston, Massachusetts, USA

Correspondence: Steven P. Treon (steven_treon@dfci.harvard.edu)

Accepted: 22 March 2025

Funding: S.P.T. is supported by a Leukemia and Lymphoma Society Translational Research Grant, and a Legacy Award from the International Waldenstrom's Macroglobulinemia Foundation.

Keywords: BTK | CXCR4 | lymphoplasmacytic lymphoma | MYD88 | TP53 | Waldenström macroglobulinemia

ABSTRACT

Waldenström macroglobulinemia (WM) is an IgM secreting lymphoplasmacytic lymphoma. Mutations in MYD88 (95%–97%) and CXCR4 (30%–40%) are common in patients with WM. TP53 is also altered in up to 30% of WM patients, particularly those previously treated. Mutated MYD88 triggers the expression and activation of HCK that drives multiple pro-survival signaling cascades, including BTK. There are over 40 CXCR4 mutation types in WM. WM patients bearing nonsense CXCR4 variants can present with symptomatic hyperviscosity and show greater resistance to covalent BTK inhibitors (cBTK-i). The cBTK-i zanubrutinib shows greater response activity and/or improved progression-free survival in WM patients with wild-type MYD88, mutated CXCR4, or altered TP53. New or emerging options for patients progressing on c-BTKi include pirtobrutinib, BGB-16673, venetoclax, and sonrotoclax. Combinations of BTK inhibitors with chemoimmunotherapy and BCL2 antagonists have advanced. Algorithms for patients with treatment-naïve and previously treated WM based on genomics, disease characteristics, and co-morbidities are discussed.

1 | Introduction

Waldenström macroglobulinemia (WM) is a B-cell lymphoid neoplasm resulting from the accumulation of a clonal population of lymphocytes, lymphoplasmacytic cells, and plasma cells, which secrete a monoclonal IgM. WM corresponds to lymphoplasmacytic lymphoma (LPL) as defined in the International Consensus Classification of Mature Lymphoid Neoplasms, and the World Health Organization classification systems [1, 2]. Most cases of LPL are WM; < 5% of cases are IgA-secreting, IgG-secreting, or non-secreting LPL [2]. The key mutations in WM include MYD88, CXCR4, and TP53. Up to half of WM patients have loss of the long arm (q) of chromosome 6. Acquired BTK mutations are common in those patients who progress on BTK

inhibitors. The importance of these mutations to the pathogenesis and management of WM is discussed below.

2 | MYD88 Mutations

Mutated MYD88 (MYD88^{Mut}) is found in 95%–97% of WM patients, nearly all of which are of the L265P variant [3–8]. AS-PCR is preferable for MYD88^{L265P} detection since next-generation sequencing (NGS) may miss MYD88^{L265P} in 35% of WM patients, particularly in those with a bone marrow (BM) disease burden of < 10% [9]. The signaling cascades triggered by MYD88^{Mut} are exhibited in Figure 1, and are dependent on Hematopoietic Cell Kinase (HCK) BTK and IL-1 receptor-




FIGURE 1 | Pro-survival signaling driven by mutated MYD88 signaling. Mutated MYD88 triggers gene expression of HCK, a SRC family member. HCK triggers BTK, SYK, and ERK1/2 signaling. BTK also triggers ERK1/2 as well as NFKB p65 mediated pro-survival signaling. IRAK4/IRAK1 are activated by mutated MYD88 through an HCK independent pathway and trigger, along with BTK, NFKB-mediated pro-survival signaling.

associated kinases (IRAKs) [10–16]. HCK activates BTK-dependent NFKB and ERK1/2 signaling, whilst IRAK1 and IRAK4 molecules trigger NFKB independent of BTK. Up to 5% of WM patients are MYD88 wild-type (MYD88^{WT}). Many of these patients carry NFKB-activating mutations distal to BTK signaling [17]. MYD88^{WT} patients have a higher risk for disease transformation and show shorter overall survival (OS) [18, 19]. MYD88^{Mut} status can also differentially impact outcomes with BTK inhibitors (discussed below). Current workshop guidelines recommend the determination of MYD88^{Mut} status as part of the diagnostic workup by AS-PCR for the MYD88^{L265P} variant. If negative, NGS may be used to identify any non-MYD88^{L265P} variants [20].

3 | CXCR4 Mutations

CXCR4^{Mut} are found in 30%–40% of WM patients [4, 21]. Over 40 CXCR4 nonsense and frameshift variants in the C-terminal domain have been identified in WM patients [4, 7, 22–25]. Nonsense (CXCR4^{Mut/NS}) variants such as CXCR4^{S338X} cause truncation of the C-terminal regulatory domain while frameshift (CXCR4^{Mut/FS}) variants result from insertions or deletions [4, 21, 26, 27]. In response to CXCL12, CXCR4^{Mut} triggers BTK, AKT, and ERK signaling, which promotes BM chemotaxis and ibrutinib-resistance [22–24]. CXCR4 antagonists such as plerixafor or ulocuplumab can sensitize CXCR4^{Mut}-expressing WM cells to ibrutinib [22–24].

CXCR4^{Mut/NS} WM patients present with higher BM disease burden and serum IgM (sIgM) levels and are more likely to have

symptomatic hyperviscosity. CXCR4^{Mut} patients, particularly those with nonsense variants, may also have a shorter time to initial treatment versus those with either CXCR4^{WT} or CXCR4^{Mut/FS} [7, 26, 27]. One study also showed shorter OS in patients with CXCR4^{Mut/NS} versus CXCR4^{WT} or CXCR4^{Mut/FS} [25]. CXCR4^{Mut/NS} may also adversely impact treatment outcomes with BTK inhibitors versus CXCR4^{WT} or CXCR4^{Mut/FS} [28]. The importance of CXCR4^{Mut} subtype on ibrutinib outcomes was evaluated in 180 symptomatic WM patients receiving ibrutinib. CXCR4^{Mut/NS} was associated with lower major response rate (MRR) and shorter PFS versus those with CXCR4^{Mut/FS} or CXCR4^{WT} [28]. NGS may miss two-thirds of patients with CXCR4^{Mut}, particularly those with lower BM disease burden and clonality [29]. Newer NGS platforms may improve detection [25]. Current workshop guidelines recommend that CXCR4^{Mut} status be considered part of the diagnostic workup by NGS, particularly in patients being considered for BTK inhibitor therapy [20].

4 | TP53 Alterations

Alterations in TP53 (TP53^{Alt}) occur in 5%–15% of treatment-naïve WM patients, including TP53^{Mut} and 17p deletions [7, 30, 31]. The incidence of TP53^{Alt} appears higher (25%–30%) in previously treated WM patients, most of whom received alkylators (85%) and/or nucleoside analogs (22%) [32]. TP53^{Alt} WM patients show shorter OS and/or PFS with BTK inhibitors [30–32]. Current workshop guidelines recommend evaluating for TP53^{Alt} at diagnosis and relapse using NGS as their presence

may guide treatment considerations [20]. As these studies have been qualitative, no cutoffs for TP53^{Alt} have been established.

5 | Deletions in Chromosome 6q

Deletions in 6q (del6q) are present in up to half of WM patients at diagnosis and are almost always are heterozygous. 6q is of particular interest since important regulators of BTK (IBTK), MYD88/NFκB (TNFAIP3, HIVEP2, TRAF3IP2, IRAK1BP1), and regulators of apoptosis (FOXO3, BCLAF1, PERP) are located at this locus [33]. Serial whole exome sequencing identified homozygous deletions in 6q in WM patients progressing on ibrutinib, including evolution from heterozygous to homozygous loss of 6q at the time of progression [34].

6 | BTK Mutations

BTK^{Cys481} is the binding site for covalent BTK inhibitors (cBTK-i), including ibrutinib, zanubrutinib, acalabrutinib, orelabrutinib and tirabrutinib. BTK^{Cys481} variants are the most common mutations associated with acquired ibrutinib-resistance in WM patients [35]. Multiple clones bearing different BTK^{Cys481} mutations can occur within individual WM patients who progress on ibrutinib [35]. WM cells expressing the BTK^{Cys481Ser} mutation show ibrutinib-resistance and re-activation of BTK-PLCγ2-ERK1/2 signaling [16]. Use of ERK1/2 inhibitors triggers apoptosis in BTK^{Cys481Ser} expressing cells, and re-sensitization to ibrutinib [16]. Moreover, ERK1/2 re-activation is accompanied by IL-6 and IL-10 release which protects co-cultured wild-type

BTK^{Cys481} WM cells from ibrutinib, demonstrating a paracrine means for propagating cBTK-i resistance [16].

7 | Genomics and Treatment Approach in WM

Figure 2 provides an algorithm for symptomatic, treatment-naïve WM patients based on underlying tumor genomics. The recommendations presented below considered recent consensus panel guidance [38]. For symptomatic treatment-naïve patients, chemoimmunotherapy with bendamustine and rituximab (Benda-R), dexamethasone, rituximab, and cyclophosphamide (DRC), as well as cBTK-i can be considered. For chemoimmunotherapy, Benda-R may offer an advantage over DRC since the former may offer deeper responses and longer PFS [40, 41].

For MYD88^{Mut} only patients, using a cBTK-i may be appropriate to minimize the risk for acquired TP53^{Alt}. As all cBTK-i exhibit similar activity in MYD88^{Mut} only patients, the choice should consider accessibility and adverse event profile, including risk for atrial fibrillation in patients at risk [38]. For CXCR4^{Mut} patients requiring a rapid response, Benda-R or zanubrutinib are active options [36, 39, 42, 43]. Rituximab should be held in any rituximab-containing regimens, and plasmapheresis should be performed in those with symptomatic hyperviscosity. Rituximab should also be held in patients without symptomatic hyperviscosity and chemotherapy offered alone until the serum IgM levels are < 4000 mg/dL to avoid triggering a hyperviscosity crisis [38]. The median time to a major response was 2.8 months in CXCR4^{Mut} WM patients receiving zanubrutinib in the ASPEN study, comparable to Benda-R [39]. Benda-R may be preferable




FIGURE 2 | Genomic based treatment algorithm for symptomatic, treatment Naïve patients with Waldenström macroglobulinemia. Clinicians should consult local regulatory approvals and guidelines for BTK inhibitor status and use in WM. The algorithm represents the authors' recommendations (see Treon et al. [36]) and their practice experiences in WM patients. Recommendations are intended for educational purposes. Rituximab should be held if chemoimmunotherapy is chosen until the serum IgM levels are < 4000 mg/dL to avoid triggering or exacerbating a hyperviscosity crisis. Benda-R can be considered for patients with bulky adenopathy or extramedullary disease. PI-based therapy or Benda-R can be considered for symptomatic amyloidosis with autologous stem cell transplantation as consolidation in select patients (see Merlini et al. [37]). Rituximab alone or with ibrutinib if MYD88^{Mut} or Benda-R are options for patients with IgM demyelinating peripheral neuropathy depending on severity and pace of progression. Maintenance rituximab may be considered in patients > 65 years responding to chemoimmunotherapy with rituximab (see Buske et al. [38]). Rituximab, cyclophosphamide, and dexamethasone (RCD) is an option for chemoimmunotherapy if Benda-R is not accessible (see Buske et al. [38]). ¹Zanubrutinib may also be prioritized for those with TP53 alterations (see Tam et al. and Dimopoulos et al. [32, 39]). ²Benda-R is preferable over PI-based regimens for those with bulky disease. Clinical trial options should always be considered. Benda, bendamustine; CAGG, cold agglutinins; CRYOS, cryoglobulinemia; HV, hyperviscosity; PI, proteasome-inhibitor; PN, peripheral neuropathy; R, rituximab.

in patients with bulky disease or symptomatic light chain amyloidosis [36, 38].

Zanubrutinib can also be considered in CXCR4^{Mut} patients who do not need rapid disease control since a shorter time to major response, deeper responses, and longer PFS were observed versus ibrutinib [39]. For MYD88^{WT} patients, zanubrutinib is favored for symptomatic, treatment-naïve patients since high response levels and long-term disease control can be achieved [39]. Benda-R and proteasome-inhibitor (PI)-based therapy are reasonable alternatives in CXCR4^{Mut} or MYD88^{WT} patients [38]. TP53^{Alt} status can be considered in positioning BTK inhibitors. Zanubrutinib is preferable for TP53^{Alt} WM patients given the ASPEN study findings showing higher levels of activity and long-term disease control versus ibrutinib [32, 39].

Figure 3 provides an algorithm for symptomatic, previously treated WM patients. The recommendations considered recent consensus panel guidance [43]. The consensus panel noted that biological age, co-morbidities and fitness, nature of relapse, patient preferences, hematopoietic reserve, and MYD88, CXCR4, and TP53 mutation status should be considered in treatment selection. For MYD88^{Mut} only patients who are refractory or in first relapse following initial chemoimmunotherapy, cBTK-i can be considered. As all cBTK-i exhibit similar response activity in MYD88^{Mut} only patients, the choice of agent should consider accessibility, disease morbidity, and adverse event profile in WM (summarized in Treon et al. [36]). For MYD88^{Mut}CXCR4^{Mut} patients who are refractory or in first relapse after initial

chemoimmunotherapy, zanubrutinib may be preferable [36]. In MYD88^{WT} WM patients, zanubrutinib is preferable after initial chemoimmunotherapy [32, 39]. Zanubrutinib is also preferred for TP53^{Alt} WM patients, as noted above [32, 39].

Benda-R is preferable regardless of genomic subtype for WM patients who are refractory to initial cBTK-i therapy [36]. As discussed above, rituximab should be held in any rituximab-containing regimens, and plasmapheresis should be performed in those with symptomatic hyperviscosity. Rituximab should also be held in patients without symptomatic hyperviscosity and chemotherapy offered alone until the serum IgM levels are < 4000 mg/dL to avoid triggering a hyperviscosity crisis [38, 43]. For those progressing after initial cBTK-i response, options include Benda-R, PI-based therapy, venetoclax, or pirtobrutinib. Alkylator exposure should be avoided, particularly in patients < 70 years or with TP53^{Alt}. Venetoclax may be preferable for these patients since it is highly active in WM patients previously exposed to cBTK-i or with CXCR4^{Mut} disease [44, 45]. The activity of venetoclax in MYD88^{WT} or TP53^{Alt} WM patients remains to be clarified. Pirtobrutinib is an option post-cBTK-i therapy, though its activity in MYD88^{WT} or MYD88^{Mut}CXCR4^{Mut} patients is not known [46, 47]. Benda-R or PI-based regimens can also be considered for those progressing on a cBTK-i as these regimens appear active across all genomic subtypes [36, 42, 48]. Additional options in second or later relapse include re-use of chemotherapy if a response lasted for > 3 years, alternative chemoimmunotherapy, nucleoside analogs, or everolimus [38]. Clinical trials should also be prioritized in patients with relapsed disease.




FIGURE 3 | Genomic based treatment algorithm for symptomatic, previously treated patients with Waldenstrom macroglobulinemia. Clinicians should consult local regulatory approvals and guidelines for BTK inhibitor status and use in WM. The algorithm represents the recommendations of the authors based on clinical trial data summarized in the text, consensus recommendations (see Treon et al. [36]), and their practice experiences in WM patients. Recommendations are intended for educational purposes. See also notations for Figure 2. Nucleoside analogs should be avoided in younger patients and candidates for autologous stem cell transplantation (ASCT). ASCT may be considered in patients with multiple relapses and chemosensitive disease, and those with systemic light chain amyloidosis for consolidation after PI or Benda-R therapy (see Merlini et al. [37]).¹Zanubrutinib may also be prioritized for those with TP53 alterations (see Tam et al. and Dimopoulos et al. [32, 39]).²Benda-R is preferable over PI-based regimens for those with bulky disease. Clinical trial options should always be considered.

Benda-R is more suitable for WM patients with bulky extramedullary disease since data on BTK inhibitors in patients with bulky disease is limited. For WM patients with symptomatic light chain amyloidosis, consensus recommendations favor Benda-R or PI-based therapy followed by consolidation with high-dose chemotherapy and autologous stem cell transplant in suitable WM patients [37]. Covalent BTK-inhibitors are highly active and show durable responses in WM patients with CNS disease (Bing Neel Syndrome) [49–51].

8 | Emerging Treatment Options

Newer agents being developed for WM include the BTK degrader BGB-16673 and the BCL2 inhibitor sonrotoclax. In 27 heavily pre-treated WM patients (median prior therapies of 3), the overall and major response rates to single-agent BGB-16673 were 82% and 74% and were not impacted by MYD88, CXCR4 or TP53 mutation status [52]. Responses were observed in patients carrying BTK mutations associated with acquired resistance to covalent (BTK^{Cys481}) and non-covalent (BTK^{Leu528}) BTK inhibitors. Treatment was well tolerated, and no episodes of atrial fibrillation were observed. The efficacy of single-agent sonrotoclax has also been evaluated in a Phase 1 study in 19 previously treated WM patients. In this Phase 1 study, patients received 80, 160, and 320 mg daily. The overall and major response rates were 79% and 58% [53].

Combination studies are also underway with BTK and BCL2 inhibitors in WM. Zanubrutinib in combination with ixazomib and dexamethasone (ZID) is being investigated in a study in China (NCT04463953) and has shown high levels of response activity and good tolerance in symptomatic, treatment-naïve patients [54]. The overall, major, and VGPR/CR remission rates were 100%, 96%, and 46%, respectively. The median time to response was 2 months. Patients with mutations in *CXCR4* had similar VGPR/CR rates. The combination of Benda-R with acalabrutinib is being investigated in a multicenter (BRAWM Study) as first line therapy in WM [55]. Patients received 1 year of acalabrutinib along with 6 cycles of Benda-R. In a preliminary report, the major response rate was 100%, with 42% of patients achieving a VGPR/CR. Patients without *CXCR4* mutations showed better VGPR/CR rates at cycle 12. The multicenter ZEBRA study has recently been initiated, and it will combine 15 months of zanubrutinib with four cycles of Benda-R (NCT06561347). The combination of pirtobrutinib with venetoclax is also being investigated in previously treated, symptomatic patients (NCT05734495) [56]. Patients receive 2 years of treatment in this study. The MRR was 87% in a preliminary report, with similar responses regardless of *CXCR4* mutation status or previous covalent BTK inhibitor exposure. Combination studies with zanubrutinib and sonrotoclax are also contemplated in WM. The combination of acalabrutinib plus rituximab is also under investigation in patients with demyelinating neuropathy and concurrent IgM monoclonal gammopathy (NCT05065554). In Germany, the CZAR-1 study is investigating the efficacy and safety of carfilzomib in combination with ibrutinib versus ibrutinib alone in treatment-naïve and previously treated WM (NCT04263480). A second German study is also investigating the combination of Benda-R and ibrutinib

(NCT03620903). Immunotherapies targeting WM are also advancing. A clinical trial with the antibody drug conjugate locastuximab tesirine that targets CD19 is enrolling WM patients with symptomatic, previously treated WM (NCT05190705). A study with the CD3/CD20 bispecific antibody epcoritamab has also been initiated in symptomatic previously treated WM (NCT06510491).

Conflicts of Interest

S.P.T. received research funding, and/or consulting fees from Abbvie/Pharmacyclics Inc., Janssen Oncology Inc., Beigene Inc., Eli Lilly Pharmaceuticals, Bristol Myers Squibb, and Ono Pharmaceuticals. S.P.T. is a named inventor for MYD88 and CXCR4 testing for WM and has assigned all interests to his institution. J.J.C. received research funds from Abbvie, AstraZeneca, Beigene, Cellectar, LOXO, and Pharmacyclics and honoraria from Abbvie, Beigene, Cellectar, Janssen, Kite, LOXO, Mustang Bio, Nurix, and Pharmacyclics. S.S. received research funding and/or consulting fees from Beigene, Cellectar Biosciences, Astra Zeneca, and ADC Therapeutics.

Data Availability Statement

The manuscript represents a review. Citations for sources of data are provided.

Peer Review

The peer review history for this article is available at <https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/hon.70071>.

References

1. E. Campo, E. S. Jaffe, J. R. Cook, et al., “The International Consensus Classification of Mature Lymphoid Neoplasms: A Report From the Clinical Advisory Committee,” *Blood* 140, no. 11 (2022): 1229–1253, <https://doi.org/10.1182/blood.2022015851>.
2. R. Alaggio, C. Amador, I. Anagnostopoulos, et al., “The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms,” *Leukemia* 36, no. 7 (2022): 1720–1748, <https://doi.org/10.1038/s41375-022-01620-2>.
3. S. P. Treon, L. Xu, G. Yang, et al., “MYD88 L265P Somatic Mutation in Waldenstrom’s Macroglobulinemia,” *New England Journal of Medicine* 367, no. 9 (2012): 826–833, <https://doi.org/10.1056/nejmoa1200710>.
4. Z. R. Hunter, L. Xu, G. Yang, et al., “The Genomic Landscape of Waldenstrom Macroglobulinemia Is Characterized by Highly Recurring MYD88 and WHIM-Like CXCR4 Mutations, and Small Somatic Deletions Associated With B-Cell Lymphomagenesis,” *Blood* 123, no. 11 (2014): 1637–1646, <https://doi.org/10.1182/blood-2013-09-525808>.
5. C. Jiménez, E. Sebastián, M. C. Chillón, et al., “MYD88 L265P Is a Marker Highly Characteristic of, but Not Restricted to, Waldenström’s Macroglobulinemia,” *Leukemia* 27 (2013): 1722–1728, <https://doi.org/10.1038/leu.2013.62>.
6. S. Poulain, C. Roumier, A. Decambron, et al., “MYD88 L265P Mutation in Waldenstrom’s Macroglobulinemia,” *Blood* 121, no. 22 (2013): 4504–4511, <https://doi.org/10.1182/blood-2012-06-436329>.
7. M. Varettoni, L. Arcaini, S. Zibellini, et al., “Prevalence and Clinical Significance of the MYD88 (L265P) Somatic Mutation in Waldenstrom’s Macroglobulinemia and Related Lymphoid Neoplasms,” *Blood* 121, no. 13 (2013): 2522–2528, <https://doi.org/10.1182/blood-2012-09-457101>.
8. L. Xu, Z. R. Hunter, G. Yang, et al., “MYD88 L265P in Waldenström Macroglobulinemia, Immunoglobulin M Monoclonal Gammopathy, and Other B-Cell Lymphoproliferative Disorders Using Conventional and

- Quantitative Allele-Specific Polymerase Chain Reaction," *Blood* 121 (2013): 2051–2581.
9. A. Kofides, Z. R. Hunter, L. Xu, et al., "Diagnostic Next-Generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia," *Hemasphere* 5, no. 8 (2021): e624, <https://doi.org/10.1097/hs9.0000000000000624>.
 10. G. Yang, S. J. Buhrlage, L. Tan, et al., "HCK Is a Survival Determinant Transactivated by Mutated MYD88, and a Direct Target of Ibrutinib," *Blood* 127, no. 25 (2016): 3237–3252, <https://doi.org/10.1182/blood-2016-01-695098>.
 11. X. Liu, J. G. Chen, M. Munshi, et al., "Expression of the Prosurvival Kinase HCK Requires PAX5 and Mutated MYD88 Signaling in MYD88-Driven B-Cell Lymphomas," *Blood Advances* 4, no. 1 (2020): 141–153, <https://doi.org/10.1182/bloodadvances.2019000947>.
 12. G. Yang, Y. Zhou, X. Liu, et al., "A Mutation in MYD88 (L265P) Supports the Survival of Lymphoplasmacytic Cells by Activation of Bruton Tyrosine Kinase in Waldenström Macroglobulinemia," *Blood* 122, no. 7 (2013): 1222–1232, <https://doi.org/10.1182/blood-2012-12-475111>.
 13. M. Munshi, X. Liu, J. G. Chen, et al., "SYK Is Activated by Mutated MYD88 and Drives Pro-survival Signaling in MYD88 Driven B-Cell Lymphomas," *Blood Cancer Journal* 10, no. 1 (2020): 12, <https://doi.org/10.1038/s41408-020-0277-6>.
 14. M. Munshi, X. Liu, A. Kofides, et al., "A New Role for the SRC Family Kinase HCK as a Driver of SYK Activation in MYD88 Mutated Lymphomas," *Blood Advances* 6, no. 11 (2022): 3332–3338, <https://doi.org/10.1182/bloodadvances.2021006147>.
 15. G. Yang, J. Wang, L. Tan, et al., "The HCK/BTK Inhibitor KIN-8194 Is Active in MYD88-Driven Lymphomas and Overcomes Mutated BTKCys481 Ibrutinib Resistance," *Blood* 138, no. 20 (2021): 1966–1979, <https://doi.org/10.1182/blood.2021011405>.
 16. J. G. Chen, X. Liu, M. Munshi, et al., "BTK^{Cys481Ser} Drives Ibrutinib Resistance via ERK1/2 and Protects BTK^{wild-type} MYD88-Mutated Cells by a Paracrine Mechanism," *Blood* 131, no. 18 (2018): 2047–2059, <https://doi.org/10.1182/blood-2017-10-811752>.
 17. Z. R. Hunter, L. Xu, N. Tsakmaklis, et al., "Insights Into the Genomic Landscape of MYD88 Wild-Type Waldenström Macroglobulinemia," *Blood Advances* 2, no. 21 (2018): 2937–2946, <https://doi.org/10.1182/bloodadvances.2018022962>.
 18. S. P. Treon, J. N. Gustine, L. Xu, et al., "MYD88 Wild-Type Waldenström Macroglobulinemia: Differential Diagnosis, Risk of Histological Transformation, and Overall Survival," *Br J Haematol* 180, no. 3 (2018): 374–380.
 19. J. P. Abeykoon, J. Paludo, R. L. King, et al., "MYD88 Mutation Status Does Not Impact Overall Survival in Waldenström Macroglobulinemia," *American Journal of Hematology* 93, no. 2 (2018): 187–194, <https://doi.org/10.1002/ajh.24955>.
 20. R. Garcia-Sanz, M. Varettoni, J. Jimenez, et al., "Report of Consensus Panel 3 From the 11th International Workshop on Waldenström's Macroglobulinemia: Recommendations for Molecular Diagnosis in Waldenström's Macroglobulinemia," *Seminars in Hematology* 60, no. 2 (2023): 90–96, <https://doi.org/10.1053/j.seminhematol.2023.03.007>.
 21. L. Xu, Z. R. Hunter, N. Tsakmaklis, et al., "Clonal Architecture of CXCR4 WHIM-Like Mutations in Waldenström Macroglobulinemia," *British Journal of Haematology* 172, no. 5 (2016): 735–744, <https://doi.org/10.1111/bjh.13897>.
 22. A. M. Roccaro, A. Sacco, C. Jimenez, et al., "C1013G/CXCR4 Acts as a Driver Mutation of Tumor Progression and Modulator of Drug Resistance in Lymphoplasmacytic Lymphoma," *Blood* 123, no. 26 (2014): 4120–4131, <https://doi.org/10.1182/blood-2014-03-564583>.
 23. Y. Cao, Z. R. Hunter, X. Liu, et al., "The WHIM-Like CXCR4(S338X) Somatic Mutation Activates AKT and ERK, and Promotes Resistance to Ibrutinib and Other Agents Used in the Treatment of Waldenström's Macroglobulinemia," *Leukemia* 29, no. 1 (2015): 169–176, <https://doi.org/10.1038/leu.2014.187>.
 24. Y. Cao, Z. R. Hunter, X. Liu, et al., "CXCR4 WHIM-Like Frameshift and Nonsense Mutations Promote Ibrutinib Resistance but Do Not Supplant MYD88(L265P) -Directed Survival Signalling in Waldenström Macroglobulinemia Cells," *British Journal of Haematology* 168, no. 5 (2015): 701–707, <https://doi.org/10.1111/bjh.13200>.
 25. Y. Wang, V. L. Gali, Z. Xu-Monette, et al., "Molecular and Genetic Biomarkers Implemented From Next-Generation Sequencing Provide Treatment Insights in Clinical Practice for Waldenström Macroglobulinemia," *Neoplasia* 23, no. 4 (2021): 361–374.
 26. S. P. Treon, Y. Cao, L. Xu, G. Yang, X. Liu, and Z. R. Hunter, "Somatic Mutations in MYD88 and CXCR4 Are Determinants of Clinical Presentation and Overall Survival in Waldenström Macroglobulinemia," *Blood* 123, no. 18 (2014): 2791–2796, <https://doi.org/10.1182/blood-2014-01-550905>.
 27. S. Poulain, C. Roumier, A. Venet-Caillault, et al., "Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia," *Clinical Cancer Research* 22, no. 6 (2016): 1480–1488, <https://doi.org/10.1158/1078-0432.ccr-15-0646>.
 28. J. J. Castillo, L. Xu, J. N. Gustine, et al., "CXCR4 Mutation Subtypes Impact Response and Survival Outcomes in Patients With Waldenström Macroglobulinemia Treated With Ibrutinib," *British Journal of Haematology* 187, no. 3 (2019): 356–363, <https://doi.org/10.1111/bjh.16088>.
 29. J. N. Gustine, L. Xu, G. Yang, et al., "Bone Marrow Involvement and Sub-Clonal Diversity Impairs Detection of Mutated CXCR4 by Diagnostic Next-Generation Sequencing in Waldenström Macroglobulinemia," *British Journal of Haematology* 194, no. 4 (2021): 730–733, <https://doi.org/10.1111/bjh.17385>.
 30. S. Poulain, C. Roumier, E. Bertrand, et al., "TP53 Mutation and Its Prognostic Significance in Waldenström's Macroglobulinemia," *Clinical Cancer Research* 23, no. 20 (2017): 6325–6335, <https://doi.org/10.1158/1078-0432.ccr-17-0007>.
 31. J. N. Gustine, N. Tsakmaklis, M. G. Demos, et al., "TP53 Mutations Are Associated With Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström Macroglobulinemia," *British Journal of Haematology* 184, no. 2 (2019): 242–245, <https://doi.org/10.1111/bjh.15560>.
 32. C. S. Tam, S. Opat, S. D'Sa, et al., "Biomarker Analysis of the ASPEN Study Comparing Zanubrutinib With Ibrutinib for Patients With Waldenström Macroglobulinemia," *Blood Advances* 8, no. 7 (2024): 1639–1650, <https://doi.org/10.1182/bloodadvances.2023010906>.
 33. M. L. Guerrero, N. Tsakmaklis, L. Xu, et al., "MYD88 Mutated and Wild-Type Waldenström's Macroglobulinemia: Characterization of Chromosome 6q Gene Losses and Their Mutual Exclusivity With Mutations in CXCR4," *Haematologica* 103, no. 9 (2018): e408–e411, <https://doi.org/10.3324/haematol.2018.190181>.
 34. C. Jimenez, G. C. Chan, L. Xu, et al., "Genomic Evolution of Ibrutinib Resistant Clones in Waldenström Macroglobulinemia," *British Journal of Haematology* 189, no. 6 (2020): 1165–1170, <https://doi.org/10.1111/bjh.16463>.
 35. L. Xu, N. Tsakmaklis, G. Yang, et al., "Acquired Mutations Associated With Ibrutinib Resistance in Waldenström Macroglobulinemia," *Blood* 129, no. 18 (2017): 2519–2525, <https://doi.org/10.1182/blood-2017-01-761726>.
 36. S. P. Treon, S. Sarosiek, and J. J. Castillo, "How I Use Genomics and BTK Inhibitors in the Treatment of Waldenström Macroglobulinemia," *Blood* 143, no. 17 (2024): 1702–1712, <https://doi.org/10.1182/blood.2022017235>.

37. G. Merlini, S. Sarosiek, G. Benevolo, et al., "Report of Consensus Panel 6 From the 11th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis," *Seminars in Hematology* 60, no. 2 (2013): 113–117, <https://doi.org/10.1053/j.seminhematol.2023.03.002>.
38. C. Buske, J. J. Castillo, J. P. Abeykoon, et al., "Report of Consensus Panel 1 From the 11th International Workshop on Waldenström's Macroglobulinemia on Management of Symptomatic, Treatment-Naïve Patients," *Seminars in Hematology* 60, no. 2 (2023): 73–79, <https://doi.org/10.1053/j.seminhematol.2023.03.005>.
39. M. A. Dimopoulos, S. Opat, S. D'Sa, et al., "Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study," *Journal of Clinical Oncology* 41, no. 33 (2023): 5099–5106, <https://doi.org/10.1200/jco.22.02830>.
40. J. Paludo, J. P. Abeykoon, A. Shreders, et al., "Bendamustine and Rituximab (BR) Versus Dexamethasone, Rituximab, and Cyclophosphamide (DRC) in Patients With Waldenström Macroglobulinemia," *Annals of Hematology* 97, no. 8 (2018): 1417–1425, <https://doi.org/10.1007/s00277-018-3311-z>.
41. J. J. Castillo, J. N. Gustine, K. Meid, et al., "Response and Survival for Primary Therapy Combination Regimens and Maintenance Rituximab in Waldenström Macroglobulinaemia," *British Journal of Haematology* 181, no. 1 (2018): 77–85, <https://doi.org/10.1111/bjh.15148>.
42. K. Laribi, S. Poulain, L. Willems, et al., "Bendamustine Plus Rituximab in Newly-Diagnosed Waldenström Macroglobulinaemia Patients. A Study on Behalf of the French Innovative Leukaemia Organization (FILO)," *British Journal of Haematology* 186, no. 1 (2019): 146–149, <https://doi.org/10.1111/bjh.15718>.
43. S. D'Sa, J. V. Matous, R. Advani, et al., "Report of Consensus Panel 2 From the 11th International Workshop on Waldenström's Macroglobulinemia on the Management of Relapsed or Refractory WM Patients," *Seminars in Hematology* 60, no. 2 (2023): 80–89, <https://doi.org/10.1053/j.seminhematol.2023.03.003>.
44. M. S. Davids, A. W. Roberts, V. P. Kenkre, et al., "Long-Term Follow-Up of Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Treated With Venetoclax in a Phase I, First-in-Human Study," *Clinical Cancer Research* 27, no. 17 (2021): 4690–4695, <https://doi.org/10.1158/1078-0432.ccr-20-4842>.
45. J. J. Castillo, J. N. Allan, T. Siddiqi, et al., "Venetoclax in Previously Treated Waldenström Macroglobulinemia," *Journal of Clinical Oncology* 40, no. 1 (2022): 63–71, <https://doi.org/10.1200/jco.21.01194>.
46. A. R. Mato, N. N. Shah, W. Jurczak, et al., "Pirtobrutinib in Relapsed or Refractory B-Cell Malignancies (BRUIN): A Phase 1/2 Study," *Lancet* 397, no. 10277 (2021): P892–P901, [https://doi.org/10.1016/s0140-6736\(21\)00224-5](https://doi.org/10.1016/s0140-6736(21)00224-5).
47. M. L. Palomba, M. R. Patel, T. A. Eyre, et al., "Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Waldenström Macroglobulinemia: Results From the Phase 1/2 BRUIN Study," supplement, *Blood* 140, no. S1 (2022): 557–560, <https://doi.org/10.1182/blood-2022-159123>.
48. J. J. Castillo, J. N. Gustine, K. Meid, et al., "CXCR4 Mutational Status Does Not Impact Outcomes in Patients With Waldenström Macroglobulinemia Treated With Proteasome Inhibitors," *American Journal of Hematology* 95, no. 4 (2020): E95–E98, <https://doi.org/10.1002/ajh.25730>.
49. J. J. Castillo, G. Itchaki, J. Paludo, et al., "Ibrutinib for the Treatment of Bing-Neel Syndrome: A Multicenter Study," *Blood* 133, no. 4 (2019): 299–305, <https://doi.org/10.1182/blood-2018-10-879593>.
50. M. Saburi, Y. Saburi, K. Kawano, R. Sato, S. Urabe, and E. Ohtsuka, "Successful Treatment With Tirabrutinib for Relapsed Lymphoplasmacytic Lymphoma Complicated by Bing-Neel Syndrome," *International Journal of Hematology* 115, no. 4 (2022): 585–589, <https://doi.org/10.1007/s12185-021-03246-z>.
51. S. Sarosiek, A. Ramirez-Gomez, C. A. Flynn, et al., "Zanubrutinib for the Treatment of Bing-Neel Syndrome," *British Journal of Haematology*, Online ahead of print, February 18, 2025, <https://doi.org/10.1111/bjh.20016>.
52. J. F. Seymour, C. S. Tam, C. Y. Cheah, et al., "Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degradable BGB-16673 in Patients With Relapsed or Refractory Waldenström Macroglobulinemia: Results From the Phase 1 CaDAnCe-101 Study," supplement, *Blood* 144, no. S1 (2024): 860, <https://doi.org/10.1182/blood-2024-199212>.
53. R. Garcia-Sanz, C. Cheah, C. S. Tam, et al., "Safety and Efficacy Results of a Phase 1 Study of the Novel BCL2 Inhibitor Sonrotoclax (BGB-11417) for Relapsed/Refractory Waldenström Macroglobulinemia," in *Proceedings of the 12th International Workshop on Waldenström's Macroglobulinemia* (2024), <http://waldenstromworkshop.org/index.php/abstract-submission/abstracts>.
54. X. Wenjie, Y. Yan, T. Wang, et al., "Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study," supplement, *Blood* 144, no. S1 (2024): 1648.
55. N. Berinstein, "A Phase II Trial of Bendamustine, Rituximab and Acalabrutinib in Previously Untreated Waldenström's Macroglobulinemia (BRAWM)," in *Proceedings of the 12th International Workshop on Waldenström's Macroglobulinemia* (2024), <http://waldenstromworkshop.org/index.php/abstract-submission/abstracts>.
56. J. J. Castillo, S. Sarosiek, A. R. Branagan, et al., "A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients With Waldenström Macroglobulinemia: An Interim Analysis," in *Proceedings of the 12th International Workshop on Waldenström's Macroglobulinemia* (2024), <http://waldenstromworkshop.org/index.php/abstract-submission/abstracts>.